The agenda for the 4 March 2015 Transparency Commission meeting is now available.  The Commission will consider the following technologies:

• Aflibercept (Eylea) - new indication
• Influenza vaccine (Fluenz Tetra) - new formulation
• Liraglutide (Victoza) - review of SMR & ASMR, new indication
• Levofloxacin hemihydrate (Tavanic) - new indication
• Lomitapide mesylate (Lojuxta) - review of ASMR

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-02/odj_ct_04032015__internet.pdf [French]